The University of Hong Kong | Department of Medicine

Research site

(Unclaimed)

Location

Pok Fu Lam, Room 809, Hong Kong, Guangdong, China

Site insights

Top conditions

Top treatments

Propofol

Bupivacaine

Nicotine

Cisplatin

Dexamethasone

Gemcitabine

Silver Diamine Fluoride

AgNO3

Sorafenib

Platinum

Parent organization

This site is a part of The University of Hong Kong

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 255 total trials

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling

Ischemic Stroke; Ischemic Attack, Transient

Drug: Placebo

Drug: Milvexian

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Tepotinib

Drug: Osimertinib

Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting

Immunoglobulin A Nephropathy

IgA Nephropathy

Drug: Placebo

Drug: Atrasentan

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor...

Active, not recruiting

Breast Cancer

Melanoma

Drug: Entrectinib

Futibatinib in Patients With Specific FGFR Aberrations

The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients wil...

Active, not recruiting

Advanced or Metastatic Solid Tumor

Myeloid or Lymphoid Neoplasms (MLN)

Drug: Futibatinib

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...

Enrolling

Triple Negative Breast Cancer

Biological: adagloxad simolenin combined with OBI-821

Other: Standard of care treatment